Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century
- Dianne Pulte†1, 2Email author,
- Benjamin Barnes†3,
- Lina Jansen1,
- Nora Eisemann4,
- Katharina Emrich5,
- Adam Gondos1,
- Stefan Hentschel6,
- Bernd Holleczek7,
- Klaus Kraywinkel3,
- Hermann Brenner1, 8 and
- the GEKID Cancer Survival Working Group
© Pulte et al.; licensee BioMed Central Ltd. 2013
Received: 10 July 2013
Accepted: 10 September 2013
Published: 16 September 2013
The advent of tyrosine kinase inhibitors has produced 5-year survival of 90 + % for chronic myelocytic leukemia (CML) patients in clinical trials. However, population level survival has been lower, especially in older patients. Here, we examine survival of patients with CML in Germany and compare it to survival of patients in the United States (US).
Data were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer registries in Germany. Patients 15–69 years old diagnosed with CML were included in the analysis. Period analysis for 2002–2006 was used to provide the most up-to-date possible estimates of five-year relative survival.
Five-year relative survival was 68.7% overall in Germany and 72.7% in the US. Survival was higher in the US for all age groups except for ages 15–39 years, but the difference was only statistically significant for ages 50–59 years (at 67.5% vs 77.7% in Germany and the US, respectively). Survival decreased with age, ranging from 83.1% and 81.9%, respectively, in Germany and the US for patients 15–39 years old to 54.2% and 54.5%, respectively, in patients 65–69 years old. Survival increased between 2002 and 2006 by 12.0% points in Germany and 17.1% points in the US.
Five-year survival estimates were higher in the US than in Germany overall, but the difference was only significant for ages 50–59 years. Survival did not equal that seen in clinical trials for either country, but strong improvement in survival was seen between 2002 and 2006.
Treatment for chronic myelocytic leukemia (CML) has changed dramatically over the past several decades, especially in the early 21st century. Prior to the late 1980s, treatment was limited to chemotherapy, with a poor chance of 5-year survival for any patient subpopulation [1–3]. In the late 1980s-1990s, newer treatment options, including interferon-α [4, 5] and hematopoietic stem cell transplant (HSCT) [6, 7] became available, improving survival for some subpopulations. However, each of these treatment options is limited in its scope. Interferon-α is poorly tolerated in many patients, and only a subset of patients will respond. HSCT can be used only if a donor is available and, especially in the early years of HSCT development, only in younger and healthier patients. In 2001, the first targeted treatment for CML, imatinib, a tyrosine kinase inhibitor (TKI) , became available in Germany  and the US . This medication was well tolerated and provided complete response in the majority of patients. Additionally, it can be used in sicker and older patients with less concern about toxicity. Clinical trials of CML patients in chronic phase treated with imatinib showed 5-year survival rates of nearly 90% and up to 95% when only CML related events were considered [11, 12]. Newer tyrosine kinase inhibitors have shown even higher response rates and better survival, often with less toxicity [13, 14].
Estimates of CML patient survival in the overall population have shown dramatic increases, especially for children and younger adults. However, survival has lagged in older adults. Additionally, the majority of population-level survival estimates for CML patients are derived from studies of the Surveillance, Epidemiology, and End Results (SEER) database in the United States [15–17] or from small series within Europe [18–20], with no prior studies concentrating specifically on CML patient survival in Germany. In the past, examination of population level survival with rare cancers in Germany has been hampered by lack of high quality data from a unified database. Recently, a collaborative project funded by the German Cancer Aid was set up between 11 population based German cancer registries and the German Cancer Research Center to provide comprehensive data on cancer survival in Germany . This collaboration allows examination of detailed survival with rare cancers such as CML.
Here, we examine survival of patients diagnosed with CML in Germany between 1997 and 2006. Because age is an important prognostic factor in CML, we examine survival by age group as well as overall. Comparison is made to survival in the US using the SEER13 database.
Number of cases and percentage of cases diagnosed by death certificate only by registry of patients age 15–69 diagnosed with CML
Underlying population in 2006 (millions)
Missing date (excluded)
Cases in the analysis
Median age at diagnosis
Microscopically confirmed cases
In order to compare population-level survival for CML patients in Germany with survival in the United States (US), data from the Surveillance, Epidemiology, and End Results (SEER13) database were analyzed . The same inclusion criteria as for patients from the German cancer registries were applied for the same time period. The SEER13 database includes data from 13 regional cancer centers in the US, covering a population of about 39 million people. Centers are chosen for inclusion based on their high quality and epidemiologically interesting population groups. The SEER population is considered to be similar to the general US population with respect to most sociodemographic characteristics, although it may be more affluent than average and may have slightly higher than average survival for some cancers .
Five-year relative survival estimates for the time period 2002–2006 were calculated using period analysis . Period analysis, first introduced in 1996 , provides more up-to-date survival estimates than traditional cohort based analysis. In particular, it has been shown by extensive empirical evaluation, that period estimates of 5-year relative survival for a given period quite closely predict 5-year relative survival later observed for patients diagnosed during the period of interest [26, 27]. In order to ensure comparability of survival estimates between both countries, age-adjusted survival estimates were derived by computing weighted sums of age-specific survival estimates using weights according to the proportion of cases in the age groups (15–39, 40–49, 50–59, 60–64, and 65–69) in Germany. Because survival of patients with CML varies with age and gender , we examined survival by major age groups as above and by gender. Differences in survival between men and women, as well as between patients in Germany and the US, were tested for statistical significance, overall and by single age groups, using model-based period analysis . Additionally, model-based period analysis  was also employed to estimate changes in 5-year relative survival within the 2002–2006 period.
Relative survival was calculated as the ratio of actual survival to expected survival. Expected survival was estimated according to the Ederer II method  using national life tables. For German patients, life tables stratified by age, sex, and calendar year were obtained from the German Federal Statistical Office. Relative survival for the US patients was calculated using US sex-, age-, calendar year-, and race-specific life tables published by the Center for Disease Control (CDC) .
Percentages of cases diagnosed by death certificate only according to age in Germany and the US
Five year relative survival of patients diagnosed with CML in Germany and in the US
Five year relative survival of patients diagnosed with CML in Germany and in the US, excluding registries with more than 12% of cases reported by DCO
Five year relative survival of patients diagnosed with CML in Germany and the US for (a) men and (b) women, 2002–06
Survival of patients diagnosed with CML in Germany and the US, 2002 versus 2006
Treatment for CML has changed substantially over the first few years of the 21st century. Until 2001, the standard treatment for CML was hematopoietic stem cell transplant, if possible, and interferon-α with hydroxyurea and other chemotherapeutic agents used in cases of poor response or intolerance to interferon or lack of donor or inability to tolerate transplant. In May, 2001, imatinib, the first TKI specifically developed to block the activity of the Bcr-abl protein, was approved for use in CML in the United States . It was approved for use in Germany in November, 2001 as well  and quickly gained acceptance as the new standard of care. The initial study of imatinib in chronic phase CML showed response rates of 90% or higher for recipients . Subsequent studies of other TKIs have also shown very high response rates and durable remissions [12, 13]. However, population level data have generally shown a discrepancy between the results obtained in these trials and survival in the general population, especially in older patients [3, 15, 16]. Although use of imatinib in older patients has been shown to be safe and effective in clinical trials [33, 34], its use in older patients in the general population has lagged .
The improvement in survival between 2002 and 2006 may be partly driven by increased uptake of imatinib in that time period and possibly to initiation of the medication sooner after diagnosis, specifically use on patients still in the chronic phase where it is most effective. Although there is little data directly addressing uptake of specific medications in different countries, one study suggests that there was rapid uptake of imatinib in both Germany and the US . Additionally, a survey of physicians in the US and Europe (including, but not limited to, Germany) regarding practice in 2005–06 showed that physicians surveyed in each location chose TKI for first line therapy in most situations, including treatment of older patients. Overall, major differences in practice were not observed. However, use of pre-TKI options after failure of first line TKI in older patients (i.e. interferon or hydroxyurea) was more common among European physicians, possibly suggesting a lower uptake of second generation TKI, especially for older patients . It should be noted that more physicians in Europe were familiar with testing for mutations in Bcr-abl that lead to TKI resistance, possibly explaining the differences in therapy plans observed. Since this study did not specifically examine treatment patterns in Germany, it is not possible to say whether the results are reflective of standard practice in Germany versus other parts of Europe. Additionally, physicians who responded to the survey may not represent typical practice as they are to some degree self-selected.
Because period analysis of survival in 2002–2006 uses data from patients diagnosed as early as 1997, the extra six months of generally available imatinib in 2001 may also give the US an advantage in terms of survival estimates, especially in, but not limited to, earlier time periods. Additional factors, including later diagnosis, differences in tumor biology, and random fluctuation of response in a rare disease should also be considered. A larger percentage of German patients were diagnosed at age 60–69, which may suggest delay in diagnosis in Germany or possibly differences in tumor biology. However, it should be noted that the median age of the population in Germany is older than in the US and thus it is difficult to draw definitive conclusions from this finding.
Strengths of our study include the use of large databases with survival information from a broad sampling of each country, allowing for evaluation of survival and subgroup analysis of this rare tumor and decreasing the risk that survival differences between individual parts of the country will unduly influence the impression of survival in the country overall. Use of population-level data provides a more realistic picture of diffusion of changes in the standard of care and of how probable a patient with a given disease in the general population is to survive in contrast to data provided by clinical trials which tend to present the best-case scenario with respect to survival and may not be realistic for the general population. Additionally, the use of period analysis and modelled period analysis provides the most up-to-date estimates of survival possible.
In interpreting our results, several limitations should also be considered. First, despite the large population bases, the relative rarity of CML limits our ability to detect minor differences in survival. Second, in the absence of a national death index in Germany, most cancer registries rely on record linkage with vital statistics from the (federal) state that they cover and may miss deaths among patients who move out of the state. Nevertheless, previous validation studies have suggested potential overestimation of survival due to deaths missed by migration to be very small . Third, data on chemotherapy administration or oral therapeutic medications is available in neither the SEER nor the German database and therefore we can not make definitive statements about how use of specific medications affects survival. Fourth, there is some evidence that survival estimates from the SEER database may be higher than survival in the US population in general , so some caution is necessary when comparing survival in the two countries. Fifth, because some of the German databases are fairly new, the analysis is restricted to 5-year survival which prohibited analysis of longer survival, such as 10-year relative survival, that is of particular interest in CML. Additionally, data in this project were available only through 2006 so newer developments since the introduction of second-generation TKIs are not yet captured.
Finally and most significantly, several of the newer German registries are still in the build-up phase and the proportion of cases identified by DCO is still rather high in some of these registries. Exclusion of these DCO cases in the analysis may lead to some overestimation of survival [37, 38]. Exploring the potential magnitude of such overestimation by plausibility ranges  suggests that true survival in Germany might be up to a few percentage points lower than estimated. Thus, the survival gap between Germany and the US might be even somewhat larger than suggested by the available data, especially in the older age groups in which DCO proportions are highest. This suggestion was supported by sensitivity analyses excluding cancer registries with DCO proportions >12% which yielded somewhat lower survival estimates in Germany, especially in age group 60–69 years. Additionally, the large proportion of DCO cases in older patients (age 70+) from Germany precluded sufficiently reliable analyses for this age group which means that no conclusions can be drawn with respect to this important segment of the population.
In summary, 5-year relative survival for patients with CML is high, especially for younger patients, in both the US and Germany, although survival is higher in the US for some age groups. Survival is improving in both countries, with greater improvement seen among middle-aged patients (age 60–69) in the US, perhaps suggesting improved uptake of TKIs among these patients. Nevertheless, prognosis in this age group continues to lag behind prognosis in younger patients. Further emphasis on treatment of middle aged patients with CML and potentially further developments in the treatment of CML may continue to improve survival in this age group.
Members of the GEKID Cancer Survival Working Group: Karla Geiss, Martin Meyer (Cancer Registry of Bavaria), Andrea Eberle, Sabine Luttmann (Cancer Registry of Bremen), Roland Stabenow (Cancer Registry of Berlin and the New Federal States), Stefan Hentschel, Alice Nennecke (Cancer Registry of Hamburg); Joachim Kieschke, Eunice Sirri (Cancer Registry of Lower Saxony), Bernd Holleczek (Saarland Cancer Registry), Katharina Emrich (Cancer Registry of Rhineland-Palatinate), Hiltraud Kajüter, Volkmar Mattauch (Cancer Registry of North Rhine-Westphalia), Alexander Katalinic (Cancer Registry of Schleswig-Holstein), Benjamin Barnes, Klaus Kraywinkel (Robert Koch Institute, Berlin), Hermann Brenner, Adam Gondos, Lina Jansen (DKFZ).
This work was supported in part by a grant from the German Cancer Aid (Deutsche Krebshilfe, no. 108257) and a visiting scientist grant from the DKFZ.
- Meyskens FL, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H: Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res. 1995, 19 (9): 605-612. 10.1016/0145-2126(95)00032-J.View ArticlePubMedGoogle Scholar
- Hehlmann R, Heimpel H, Hasford J: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993, 82 (2): 398-407.PubMedGoogle Scholar
- Pulte D, Gondos A, Redaniel MT, Brenner H: Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011, 16 (5): 663-671. 10.1634/theoncologist.2010-0393.PubMed CentralView ArticlePubMedGoogle Scholar
- Hehlmann R, Heimpel H, Hasford J: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994, 84 (12): 4064-4077.PubMedGoogle Scholar
- Guilhot F, Chastang C, Michallet M: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997, 337 (4): 223-229. 10.1056/NEJM199707243370402.View ArticlePubMedGoogle Scholar
- Clift RA, Bucknew CD, Thomas ED: Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994, 84 (6): 2036-2043.PubMedGoogle Scholar
- Gale RP, Hehlmann R, Zhang MJ: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood. 1998, 91 (5): 1810-1819.PubMedGoogle Scholar
- Druker BJ, Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhitior for chronic myelogenous leukemia. J Clin Invest. 2000, 105 (1): 3-7. 10.1172/JCI9083.PubMed CentralView ArticlePubMedGoogle Scholar
- European Medicines Agency (EMEA): European public assessment report (EPAR) Glivec: EPAR summary for the public. EMEA/H/C. 2009, 406: 3-Google Scholar
- Cohen MH, Williams G, Johnson JR: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002, 8: 935-942.PubMedGoogle Scholar
- Druker BJ, Guilhot F, O’Brien SG: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355 (23): 2408-2417. 10.1056/NEJMoa062867.View ArticlePubMedGoogle Scholar
- Hochhaus A, O’Brien SG, Guilhot F: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009, 23 (6): 1054-1061. 10.1038/leu.2009.38.View ArticlePubMedGoogle Scholar
- Kantarjian HM, Shah NP, Cortes JE: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012, 119 (5): 1123-1129. 10.1182/blood-2011-08-376087.View ArticlePubMedGoogle Scholar
- Kantarjian HM, Hochhaus A, Saglio G: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011, 12 (9): 841-851. 10.1016/S1470-2045(11)70201-7.View ArticlePubMedGoogle Scholar
- Brenner H, Gondos A, Pulte D: Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008, 93 (10): 1544-1549. 10.3324/haematol.13045.View ArticlePubMedGoogle Scholar
- Brenner H, Gondos A, Pulte D: Long-term survival in chronic myelocytic leukemia after a first primary malignancy. Leuk Res. 2009, 33 (12): 1604-1608. 10.1016/j.leukres.2009.01.042.View ArticlePubMedGoogle Scholar
- Wiggins CL, Harlan LC, Nelson HE: Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. M J Med. 2010, 123 (8): 1-9. 764.eGoogle Scholar
- Lamvik J, Brinch L, Dahl IM: Chronic myeloid leukemia in health regions 1,3,4, and 5 during the period 1990–96. Tidsskr Nor Laegeforen. 1999, 119 (12): 1733-1736.PubMedGoogle Scholar
- Corm S, Roche L, Micol JB: Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990–2007: a population study. Blood. 2011, 118 (16): 4331-4337. 10.1182/blood-2011-01-330332.View ArticlePubMedGoogle Scholar
- Björkholm M, Ohm L, Eloranta S: Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011, 29 (18): 2514-2520. 10.1200/JCO.2011.34.7146.PubMed CentralView ArticlePubMedGoogle Scholar
- Hiripi E, Gondos A, Emrich K: Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol. 2012, 23 (2): 472-479. 10.1093/annonc/mdr131.View ArticlePubMedGoogle Scholar
- Surveillance, Epidemiology, and End Results (SEER): Program (www.seer.cancer.gov) Research Data (1973–2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released. 2011, April , based on the November 2010 submissionGoogle Scholar
- Mariotto A, Capocaccia R, Verdecchia A: Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control. 2002, 13: 101-111. 10.1023/A:1014380323037.View ArticlePubMedGoogle Scholar
- Brenner H, Gefeller O, Hakulinen T: Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realization and applications. Eur J Cancer. 2004, 40: 326-335. 10.1016/j.ejca.2003.10.013.View ArticlePubMedGoogle Scholar
- Brenner H, Gefeller O: An alternative approach to monitoring cancer patient survival. Cancer. 1996, 78 (9): 2004-2010. 10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
- Brenner H, Soederman B, Hakulinen T: Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol. 2002, 31 (2): 456-462. 10.1093/ije/31.2.456.View ArticlePubMedGoogle Scholar
- Brenner H, Hakulinen T: Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002, 20 (3): 826-832. 10.1200/JCO.20.3.826.View ArticlePubMedGoogle Scholar
- Sokel JE, Baccarni M, Tura S: Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985, 66 (6): 1352-1357.Google Scholar
- Brenner H, Hakulinen T: Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006, 164 (7): 689-696. 10.1093/aje/kwj243.View ArticlePubMedGoogle Scholar
- Ederer F: HH. Instructions to IBM 650 programmers in processing survival computations. 1959, Bethesda, MD: National Cancer InstituteGoogle Scholar
- Arias E: United States life tables, 2000. Natl Vit Stat Rep. 2002, 1-39.Google Scholar
- Brenner H, Gefeller O, Hakulinen T: A computer program for period analysis of cancer patients survival. Eur J Cancer. 2002, 38: 690-695. 10.1016/S0959-8049(02)00003-5.View ArticlePubMedGoogle Scholar
- Cortes J, Talpaz M, O’Brien S: Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003, 98 (6): 1105-1113. 10.1002/cncr.11629.View ArticlePubMedGoogle Scholar
- Gugliotta G, Castagnetti F, Palandri F: Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011, 117 (21): 5591-5599. 10.1182/blood-2010-12-324228.View ArticlePubMedGoogle Scholar
- Joensson B, Wilking N: A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007, 18 (Suppl 3): iii1-iii77.Google Scholar
- Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarni M, Lokey L: Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007, 109 (7): 1365-1375. 10.1002/cncr.22523.View ArticlePubMedGoogle Scholar
- Berrino F, Esteve J, Coleman MP: Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ. 1995, 132: 1-14.PubMedGoogle Scholar
- Robinson D, Sankila R, Hakulinen T, Moller H: Interpreting international comparisons of cancer survival: the effects of incomplete registration and the presence of death certificate only cases on survival estimates. Eur J Cancer. 2007, 43 (5): 909-913. 10.1016/j.ejca.2007.01.007.View ArticlePubMedGoogle Scholar
- Brenner H, Holleczek B: Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificate only. Cancer Epidemiol Biomarkers Prev. 2011, 20 (12): 2480-2486. 10.1158/1055-9965.EPI-11-0697.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.